Methods for generating hepatocytes and cholangiocytes from pluripotent stem cells

A technology of pluripotent stem cells and cholangiocytes, applied in the field of generating hepatocytes and cholangiocytes from pluripotent stem cells, which can solve problems such as no description

Active Publication Date: 2015-12-02
UNIV HEALTH NETWORK +1
View PDF9 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

While these early stages of differentiation are reasonably well established, conditions are not described: e.g. promoting maturation of hepatocytes to functional cells defined by the activity of stage I and stage II drug metabolizing enzymes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for generating hepatocytes and cholangiocytes from pluripotent stem cells
  • Methods for generating hepatocytes and cholangiocytes from pluripotent stem cells
  • Methods for generating hepatocytes and cholangiocytes from pluripotent stem cells

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0395] Endoderm induction in EBs

[0396] figure 1 In a, the strategy for generating hepatocytes from hESCs using embryoid bodies (EBs) is shown. Similar to protocols using monolayer cultures 16 , which involves a specification step that recapitulates key stages of liver development in early embryos. as previously described 18 , EBs formed from small aggregates cultured for 24 hours in low levels of BMP4. EBs were subsequently exposed to high concentrations of activin A (hereinafter referred to as activin) for five days to induce definitive endoderm, defining populations by the expression of surface markers CXCR4, CKIT, and EPCAM, and transcription factors SOX17 and FOXA2. Such as figure 1 As shown in b, more than 90% of the induced EB population co-expressed CXCR4 and CKIT or CXCR4 and EPCAM after five days of activin induction (6 days of co-culture). Intracellular flow cytometric analysis indicated that more than 90% of the population expressed SOX17, and more than 80%...

example 2

[0448] CHIR99021 is a selective inhibitor of GSK3 that has been reported to mimic the canonical Wnt signaling pathway. CHIR99021 was tested as a replacement for wnt3a (eg, added in combination with activin) in induction of embryoid bodies and for monolayer induction of definitive endoderm from hPSCs. as seen Figure 8 a) and Figure 8 b) Replacement of Wnt3a with CHIR99021 induced a proportion of CKIT+CXCR4+ and CXCR4+EPCAM+ cells greater than 95% of the population and equivalent to that seen in activin / wnt3a induction.

[0449] Figure 8 (a) and Figure 8 (b) demonstrates that CHIR99021 can induce definitive endoderm cells. Figure 8 (a) is a flow cytometric analysis showing the proportion of CXCR4+, CKIT+ and EPCAM+ cells in activin / CHIR99021 at day 6 of embryoid body induction with activin / wnt3a. Figure 8 (b) is a flow cytometric analysis showing the proportion of CXCR4+, CKIT+ and EPCAM+ cells in activin / CHIR99021 at day 6. Figure 8 (c) and Figure 8 (d) shows day...

example 3

[0455] Ectopic liver tissue in NSG mice

[0456] Transplanted hESC-derived hepatocytes engraft and generate cells expressing hepatocyte differentiation markers.

[0457] Figure 8 (e), Figure 8 (f) and Figure 8 (g) demonstrates the engraftment of ES-derived hepatocytes prepared using the method described in Example 1, except that the GSK3 inhibitor CHIR99021 was used to make the transplanted cells described in Example 2.

[0458] Figure 8 (e), Figure 8 (f) and Figure (g), Figure 8 (h) Ectopic liver tissue in NSG mice. Figure 8 (e) is an exemplary photomicrograph of H&E staining of the mesenteric region showing clusters of hESC-derived hepatocytes (arrows) 2 months after transplantation. The magnification is 5x. Intestine (arrow), implanted cells (head of arrow). Figure 8 (f) show from Figure 8 High magnification (10×) photomicrograph of the H&E stained section of (e).

[0459] Figure 8 (g), Figure 8 (h) Immunohistochemical staining showing the presence o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Methods for producing hepatocyte and/or cholangiocyte lineage cells from pluripotent stem cells, the method comprising (a) specifying the extended nodal agonist treated induced endodermal cell population to obtain a cell population comprising hepatocyte and/or cholangiocyte progenitors by contacting the extended nodal agonist treated induced endodermal cell population with specification media comprising a FGF agonist and a BMP4 agonist and/or active conjugates and/or fragments thereof; (b) inducing maturation, and optionally further lineage specification and/or expansion of the hepatocyte and/or cholangiocyte progenitors of the cell population to obtain a population comprising hepatocyte lineage cells such as hepatoblasts, hepatocytes and/or cholangiocytes, the inducing maturation step comprising generating aggregates of the cell population. Optionally, the method also comprises activating the cAMP pathway within the aggregates and forming co-aggregates.

Description

technical field [0001] The present invention relates to methods for generating functional hepatocytes from human pluripotent stem cells. Background technique [0002] The ability to generate functional hepatocytes from human pluripotent stem cells (hPSCs; including embryonic stem cells; hESCs and induced pluripotent stem cells; hiPSs) will provide a source of hepatocytes for drug metabolism studies and for cell-based cell-based therapies to address liver disease. therapy. Hepatocytes are of particular importance as they are the cells responsible for the metabolism of drugs and thus for the elimination of xenobiotics from the body 1-3 . Given this effect and individuals may vary in their ability to metabolize a particular drug 4 This fact, obtaining functional hepatocytes from representative population samples can have enormous implications for drug discovery and testing within the pharmaceutical industry. In addition to providing a new platform for drug testing, hPSC-der...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/071A61K35/12A61K35/407A61P1/16C12N5/0735C12Q1/02
CPCC12N5/067A61K35/407C12N2501/115C12N2501/119C12N2501/12C12N2501/155C12N2501/16C12N2501/415C12N2501/724C12N2506/02C12N2506/45C12N2502/00C12N5/0679C12N2501/237C12N2501/42A61P1/16C12N5/06C12N2501/01C12N2501/727C12N2501/999C12N2502/14C12N2503/02
Inventor 戈登·凯勒小川新一郎安纳德·高内卡克里斯汀·贝尔比妮塔·M·卡马斯小川美奈詹姆斯·苏拉比希特切特
Owner UNIV HEALTH NETWORK
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap